What we do

Platform

We are building a platform to identify target biomarkers and develop new digital therapeutics to treat or manage various neurological disorders.

Convergence

We take pride in our in-house convergence medical and tech professionals comprised of neurologists, software and game/VR developers, engineers, AI scientists, perceptual psychologists, and mathematicians. It enables us bring neuroscience, medicine and IT together to change how medicine is designed and delivered.

We plan to develop pipelines for various brain disorders to become a leading digital therapeutics platform company in the future.

Evidence

We have initiated a pivotal clinical trial of our first product, Nunap Vision, which provides visual perceptual training to treat visual field defects caused by brain damage. It is the first digital therapeutics clinical trial approved by MFDS (formerly known as KFDA) in South Korea. 
Nunap Vision is a SaMD (Software as a Medical Device) utilizing HMD VR. While its clinical efficacy has already been demonstrated in previous proof-of-concept studies, we designed the pivotal clinical trial to be multi-center, double-blind, randomized, and placebo-controlled for further validation.